BSE Live
Apr 17, 16:01Prev. Close
1039.10
Open Price
1074.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:50Prev. Close
1039.55
Open Price
1055.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1039.85 (6)
| Cash Flow of Venus Remedies (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 69.16 | 46.65 | 40.33 | 44.67 | 17.62 | |
| Net CashFlow From Operating Activities | 83.10 | 35.38 | 28.05 | 40.90 | 132.67 | |
| Net Cash Used In Investing Activities | -76.20 | -6.94 | -50.81 | -16.65 | 55.65 | |
| Net Cash Used From Financing Activities | 0.00 | 0.00 | 0.00 | -9.13 | -161.88 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 6.90 | 28.44 | -22.76 | 15.12 | 26.45 | |
| Cash And Cash Equivalents Begin of Year | 48.51 | 20.07 | 42.83 | 27.70 | 1.26 | |
| Cash And Cash Equivalents End Of Year | 55.41 | 48.51 | 20.07 | 42.83 | 27.70 |
30.01.2026
Venus Remedies Consolidated December 2025 Net Sales at Rs 180.26 crore, up 1.92% Y-o-Y
30.01.2026
Venus Remedies Standalone December 2025 Net Sales at Rs 179.95 crore, up 4.29% Y-o-Y
17.11.2025
Venus Remedies Consolidated September 2025 Net Sales at Rs 192.75 crore, up 15.11% Y-o-Y
12.11.2025
Venus Remedies Standalone September 2025 Net Sales at Rs 192.65 crore, up 15.35% Y-o-Y
30.01.2026
Venus Remedies Consolidated December 2025 Net Sales at Rs 180.26 crore, up 1.92% Y-o-Y
30.01.2026
Venus Remedies Standalone December 2025 Net Sales at Rs 179.95 crore, up 4.29% Y-o-Y
17.11.2025
Venus Remedies Consolidated September 2025 Net Sales at Rs 192.75 crore, up 15.11% Y-o-Y
12.11.2025
Venus Remedies Standalone September 2025 Net Sales at Rs 192.65 crore, up 15.35% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth